Please login to the form below

Not currently logged in
Email:
Password:

YM BioSciences

This page shows the latest YM BioSciences news and features for those working in and with pharma, biotech and healthcare.

Baxter and CTI's Jakafi rival clears phase III trial

Baxter and CTI's Jakafi rival clears phase III trial

Other JAK2 inhibitors coming through the pipeline for myelofibrosis include Gilead Sciences' CYT387, which it acquired as part of its $510m takeover of YM Biosciences at the end of 2012.

Latest news

  • Jakafi cleared for bone marrow disorder by FDA Jakafi cleared for bone marrow disorder by FDA

    Other JAK inhibitors coming through the pipeline include Gilead Sciences' CYT387, acquired as part of its $510m takeover of YM Biosciences at the end of 2012 and Cell Therapeutics/Baxter's

  • Feverish activity

    CIMYM (a subsidiary of YM BioSciences) is developing nimotuzumab (TheraCIM h-R3, Theraloc), an EGFR antagonist with the intent of blocking epithelial growth factor and tumour growth factor from binding to ... Another media release from YM BioSciences, in

  • Battling breast cancer

    YM Biosciences' tesmilifene is a histamine antagonist in phase III trials, which has been granted fast track status by the FDA for enhancing the activity of anthracycline chemotherapy in the treatment

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics